- Advertisement -

Editas Early Data for CRISPR Therapy EDIT-101 Shows Efficacy “Signals” in Two Patients

Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical...

UK faced with EU-US biotechnology dilemma post-Brexit – EURACTIV

The question of whether the UK will open its doors to GMOs after Brexit has become more pertinent after EU Brexit negotiator Michel Barnier...

Agricultural biotechnology center being built in Almeria – hortidaily.com

Kimitec, a company dedicated to researching, developing, and commercializing biopesticides, prebiotic biostimulants, and probiotics, has invested 50 million euros in expanding its plant in...

Cancer Drug Shortfalls Tied to How BET Inhibitors Hit BRD2 and...

For more than a decade, BET inhibitors have been touted as one of cancer therapy’s most promising drug classes. The logic was straightforward: many...

Uncountable expands specialty chemicals footprint with four new deals

Uncountable, a software company that develops AI platforms for end-to-end product development, today announced it has signed four new agreements with specialty chemicals organizations...

To Reverse Aging’s Clock, Adjust the Cell’s Machinery

If we want to increase longevity and reverse aging, we need to get serious. Forget myth. There is no fountain of youth. And we...

Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology

Register Now Erdinc Sezgin, PhD Senior LecturerKarolinska Institutet View Bio ...

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney...

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat...

Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology

Register Now Erdinc Sezgin, PhD Senior LecturerKarolinska Institutet View Bio ...

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat...

Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus

T cells are some of the immune system’s most important fighters. They can stop tumor growth and fight off severe infections. Scientists at La...

more new items

Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology

Register Now Erdinc Sezgin, PhD Senior LecturerKarolinska Institutet View Bio ...

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney...

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat...

Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for...

T cells are some of the immune system’s most important fighters. They can stop tumor growth and fight off severe infections. Scientists at La...